Production of A and C variants of staphylococcal beta-lactamase by methicillin-resistant strains of Staphylococcus aureus | Zendy

Stephen R. Norris | Zendy; Charles W. Stratton | Zendy; Douglas S. Kernodle | Zendy

Open Access

Production of A and C variants of staphylococcal beta-lactamase by methicillin-resistant strains of Staphylococcus aureus

Author(s) -

Stephen R. Norris,

Charles W. Stratton,

Douglas S. Kernodle

Publication year - 1994

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.38.7.1649

Subject(s) - microbiology and biotechnology , sulbactam , staphylococcus aureus , penicillin , cefazolin , beta lactamase , ampicillin , antibiotics , meticillin , biology , methicillin resistant staphylococcus aureus , antibacterial agent , micrococcaceae , antibiotic resistance , bacteria , escherichia coli , gene , imipenem , genetics

Most methicillin-resistant Staphylococcus aureus (MRSA) strains produce beta-lactamase. To determine whether this enzyme(s) is identical to one or more of the four beta-lactamases produced by methicillin-susceptible strains, the beta-lactamases of 50 MRSA isolates were typed by using substrate profile analysis. Forty type A, no type B, ten type C, and no type D beta-lactamase-producing strains were identified. The beta-lactamase inhibitor sulbactam reduced the MICs of beta-lactamase-labile antibiotics, including ampicillin, penicillin G, and cefazolin, for type A and type C MRSA strains.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research